Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats.

IF 2.6 4区 医学 Q3 ONCOLOGY Cancer Management and Research Pub Date : 2024-06-27 eCollection Date: 2024-01-01 DOI:10.2147/CMAR.S468453
Raz Muhammed HamaSalih
{"title":"Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats.","authors":"Raz Muhammed HamaSalih","doi":"10.2147/CMAR.S468453","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Doxorubicin (DOX) is used to treat various types of cancers. However, its use is restricted by cardiotoxicity, a leading cause of morbidity and mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may be associated with cardioprotective properties.</p><p><strong>Purpose: </strong>This study aims to determine the protective effects of different semaglutide (SEM) doses on DOX-induced cardiotoxicity in a rat model.</p><p><strong>Methodology: </strong>Thirty-five female Wistar rats were divided into five groups. The first group received distilled water as a negative control (NC); the positive control (PC) group received distilled water plus DOX; the third group (SL) received a low dose of SEM (0.06 mg/kg) plus DOX; the fourth group (SM) received a moderate dose of SEM (0.12 mg/kg) plus DOX; and the fifth group (SH) received a high dose of SEM (0.24 mg/kg) plus DOX. Blood samples were collected on day 8 to assess serum troponin, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total lipid profile, and vascular cell adhesion molecule 1 (VCAM-1). Cardiac tissue was sent for histopathological analysis.</p><p><strong>Results: </strong>DOX increased the total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), LDH, and CKP levels. Moderate and high doses of semaglutide significantly reduced serum cholesterol levels (*<i>p</i> = 0.0199), (**<i>p</i> = 0.0077), respectively. A significant reduction (***<i>p</i> = 0.0013) in total body weight after treatment with SEM was observed in the SL group and a highly significant reduction (****<i>p</i> < 0.0001) was observed in the SM and SH groups. SEM at all doses reduced CPK levels. The SL group showed a significant reduction in troponin level (*<i>p</i>=0.0344). Serum LDH levels were reduced by all three SEM doses. The histopathological findings support the biochemical results.</p><p><strong>Conclusion: </strong>Semaglutide may possess cardioprotective properties against DOX-induced cardiotoxicity in a rat model by decreasing serum biochemical markers of cardiotoxicity.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"731-740"},"PeriodicalIF":2.6000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216551/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S468453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Doxorubicin (DOX) is used to treat various types of cancers. However, its use is restricted by cardiotoxicity, a leading cause of morbidity and mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may be associated with cardioprotective properties.

Purpose: This study aims to determine the protective effects of different semaglutide (SEM) doses on DOX-induced cardiotoxicity in a rat model.

Methodology: Thirty-five female Wistar rats were divided into five groups. The first group received distilled water as a negative control (NC); the positive control (PC) group received distilled water plus DOX; the third group (SL) received a low dose of SEM (0.06 mg/kg) plus DOX; the fourth group (SM) received a moderate dose of SEM (0.12 mg/kg) plus DOX; and the fifth group (SH) received a high dose of SEM (0.24 mg/kg) plus DOX. Blood samples were collected on day 8 to assess serum troponin, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total lipid profile, and vascular cell adhesion molecule 1 (VCAM-1). Cardiac tissue was sent for histopathological analysis.

Results: DOX increased the total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), LDH, and CKP levels. Moderate and high doses of semaglutide significantly reduced serum cholesterol levels (*p = 0.0199), (**p = 0.0077), respectively. A significant reduction (***p = 0.0013) in total body weight after treatment with SEM was observed in the SL group and a highly significant reduction (****p < 0.0001) was observed in the SM and SH groups. SEM at all doses reduced CPK levels. The SL group showed a significant reduction in troponin level (*p=0.0344). Serum LDH levels were reduced by all three SEM doses. The histopathological findings support the biochemical results.

Conclusion: Semaglutide may possess cardioprotective properties against DOX-induced cardiotoxicity in a rat model by decreasing serum biochemical markers of cardiotoxicity.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
塞马鲁肽对Wistar白化大鼠多柔比星诱发的心脏毒性的影响
背景:多柔比星(DOX多柔比星(DOX)用于治疗各种癌症。然而,其使用受到心脏毒性的限制,而心脏毒性是发病和死亡的主要原因。目的:本研究旨在确定不同剂量的塞马鲁肽(SEM)对大鼠模型中 DOX 诱导的心脏毒性的保护作用:将 35 只雌性 Wistar 大鼠分为 5 组。第一组接受蒸馏水作为阴性对照(NC);阳性对照(PC)组接受蒸馏水加 DOX;第三组(SL)接受低剂量 SEM(0.06 mg/kg)加 DOX;第四组(SM)接受中等剂量 SEM(0.12 mg/kg)加 DOX;第五组(SH)接受高剂量 SEM(0.24 mg/kg)加 DOX。第8天采集血样,评估血清肌钙蛋白、乳酸脱氢酶(LDH)、肌酸磷酸激酶(CPK)、总脂质和血管细胞粘附分子1(VCAM-1)。心脏组织被送去进行组织病理学分析:结果:DOX增加了总胆固醇(TC)、低密度脂蛋白(LDL)、甘油三酯(TG)、LDH和CKP水平。中等剂量和高剂量的塞马鲁肽分别显著降低了血清胆固醇水平(*p = 0.0199)和(**p = 0.0077)。使用 SEM 治疗后,SL 组的总重量明显降低(***p = 0.0013),SM 组和 SH 组的总重量也有非常明显的降低(****p < 0.0001)。所有剂量的 SEM 都能降低 CPK 水平。SL组的肌钙蛋白水平明显下降(*p=0.0344)。三种剂量的 SEM 均降低了血清 LDH 水平。组织病理学结果支持生化结果:结论:在大鼠模型中,塞马鲁肽可通过降低血清中心脏毒性的生化指标,对DOX诱导的心脏毒性具有保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Management and Research
Cancer Management and Research Medicine-Oncology
CiteScore
7.40
自引率
0.00%
发文量
448
审稿时长
16 weeks
期刊介绍: Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
期刊最新文献
Rhabdomyolysis as a Predominant Multisystem Serious Immune-Related Adverse Event Induced by Sintilimab: A Case Report and Literature Review. Analysis of Efficacy and Survival Prognosis for Astragalus Polysaccharide Injection as Adjuvant Therapy in Non - Small Cell Lung Cancer: A Propensity Score Matching - Based Study. Alcohol Use, Coronary Heart Disease and Hypertension Modify the Predictive Accuracy of Pre-Operative CEA for TNM Staging in Chinese Colorectal Cancer Patients. Cross-Lag Analysis of Prognostic Nutritional Index and Psychosomatic Symptom Clusters in Patients with Lung Cancer: A Longitudinal Study. Manuscript Title: Analysis of the Present Status and Influencing Factors of Early Postoperative Kinesiophobia in Patients with Head and Neck Cancer: A Cross-Sectional Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1